Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosiglitazone addition versus no rosiglitazone in primary care patients with type 2 diabetes
NL-OMON25745Recruiting
- Sponsor
- Sanofi
- Start
- Dec 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of rosiglitazone in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sanofi. Started Dec 2003; status: recruiting.
02
Drugs
rosiglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON25745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25745.